ITeos Therapeutics Inc (NASDAQ: ITOS) on Tuesday, soared 7.32% from the previous trading day, before settling in for the closing price of $5.53. Within the past 52 weeks, ITOS’s price has moved between $4.80 and $18.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 12.04% annually for the last half of the decade. The company achieved an average annual earnings per share of -21.27%. With a float of $33.03 million, this company’s outstanding shares have now reached $36.57 million.
In an organization with 173 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 98.25%, operating margin of -455.79%, and the pretax margin is -348.67%.
ITeos Therapeutics Inc (ITOS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of ITeos Therapeutics Inc is 13.52%, while institutional ownership is 78.39%. The most recent insider transaction that took place on Nov 19 ’24, was worth 38,635. In this transaction Chief Financial Officer of this company bought 5,000 shares at a rate of $7.73, taking the stock ownership to the 65,429 shares.
ITeos Therapeutics Inc (ITOS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.94 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.27% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.39% during the next five years compared to -34.39% drop over the previous five years of trading.
ITeos Therapeutics Inc (NASDAQ: ITOS) Trading Performance Indicators
ITeos Therapeutics Inc (ITOS) is currently performing well based on its current performance indicators. A quick ratio of 12.62 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.49, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach -4.33 in one year’s time.
Technical Analysis of ITeos Therapeutics Inc (ITOS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.43 million. That was better than the volume of 0.32 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 74.18%. Additionally, its Average True Range was 0.41.
During the past 100 days, ITeos Therapeutics Inc’s (ITOS) raw stochastic average was set at 28.88%, which indicates a significant decrease from 57.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.26% in the past 14 days, which was higher than the 47.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.77, while its 200-day Moving Average is $10.21. However, in the short run, ITeos Therapeutics Inc’s stock first resistance to watch stands at $6.24. Second resistance stands at $6.55. The third major resistance level sits at $6.90. If the price goes on to break the first support level at $5.58, it is likely to go to the next support level at $5.23. The third support level lies at $4.92 if the price breaches the second support level.
ITeos Therapeutics Inc (NASDAQ: ITOS) Key Stats
Market capitalization of the company is 226.68 million based on 38,194K outstanding shares. Right now, sales total 35,000 K and income totals -134,410 K. The company made 0 K in profit during its latest quarter, and -45,360 K in sales during its previous quarter.
